Avalon GloboCare (NASDAQ:ALBT) is a dynamic biotechnology company devoted to advancing innovative cellular therapeutics and diagnostics to combat a wide range of diseases, including cancer and infectious diseases. With a keen focus on cell-based technologies, Avalon GloboCare is engaged in developing cutting-edge therapies and medical solutions that aim to redefine healthcare treatment paradigms. The company's objectives are centered on expediting the clinical development of its flagship products, making significant strides in cellular immunotherapy, and expanding its global research and development footprint to bring transformative healthcare solutions to patients worldwide.